ByteDance Secures $29.6 Billion Loan to Boost AI Investment 
Milei Threatens Falkland Oil Firms With Sanctions 
SpaceX Turbine Push Unlikely to Threaten Howmet, Bernstein Says 
OpenAI Nears Astra AI Model Launch With Safety Focus 
South Korea, US Discuss Chip Investments Amid Tariff Plans 
Deutsche Telekom Shares Rise as Elliott Pushes Against T-Mobile Merger 
GSM Eyes US, Europe Expansion Ahead of 2028 Hong Kong IPO 
Anthropic IPO Marketing Expected to Start in Mid-October 
Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
Berkshire Hathaway Eyes Bigger Stakes in Japan’s Top Trading Houses 
Qantas Near-Miss Raises Sydney Air Traffic Controller Fatigue Concerns 
BP Names Ian Tyler Permanent Chairman After Governance Shake-Up 
Nvidia Eyes $2.5 Billion Investment in Thinking Machines Lab 
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
Adobe Names Anil Chakravarthy CEO as AI Push Accelerates 
Lynas Rare Earths Shares Rise After Takeover Talks Revealed 
Add as a preferred source on Google
CAMBRIDGE, Mass., Feb. 28, 2018 -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of curative therapeutics using CRISPR/Cas9 technology, will participate at the following upcoming healthcare conferences in March:
Tuesday, March 13, 2018
Barclays Capital Global Healthcare Conference
Who: John Leonard, M.D., Chief Executive Officer and President
Location: Miami, Florida
Presentation Time: 3:50pm EST
Tuesday, March 20, 2018
Morgan Stanley Healthcare Corporate Access Day
Who: Tom Barnes, Ph.D., Senior Vice President, Innovative Sciences
Location: Boston, Massachusetts
One on one meetings only
Wednesday, March 21, 2018
Oppenheimer & Co. 28th Annual Healthcare Conference
Who: Tom Barnes, Ph.D., Senior Vice President, Innovative Sciences
Location: New York, New York
Presentation Time: 1:35pm EST
A live webcast of Intellia’s presentations will be accessible through the Events and Presentations page of the Investor Relations section of the company’s website at www.intelliatx.com. To access the webcasts, please log on to the Intellia website approximately 15 minutes prior to the start time to ensure adequate time for any software downloads that may be required. A replay of the webcast will be available on Intellia’s website for 14 days following each conference.
About Intellia Therapeutics
Intellia Therapeutics is a leading genome editing company focused on the development of proprietary, curative therapeutics using the CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course. The combination of deep scientific, technical and clinical development experience, along with its leading intellectual property portfolio, puts Intellia in a unique position to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create a new class of therapeutic products. Learn more about Intellia Therapeutics and CRISPR/Cas9 at intelliatx.com; Follow us on Twitter @intelliatweets.
Investor Contact:
Lindsey Trickett
Vice President, Investor Relations
+1 857-285-6211
[email protected]
Media Contact:
Jennifer Mound Smoter
Senior Vice President, External Affairs & Communications
+1 857-706-1071
[email protected]
